The prognostic importance of RAS and BRAF V600E mutations in stage III colon cancer should be validated for stage II. An immunoscore for quantifying lymphocytic infiltration has been standardized and validated for prognostic value in localized colon cancer. Various histoprognostic scores and molecular classifications have also shown promising results in predicting survival outcomes in colorectal cancer.